Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
Publication Date: August 3, 2022
Last Updated: August 4, 2022
Summary of Recommendations
For patients with CRC being considered for immune checkpoint inhibitor therapy, pathologists should use MMR-IHC and/or MSI by PCR for the detection of DNA MMR defects. Although MMR-IHC or MSI by PCR are preferred, pathologists may use a validated MSI by NGS assay for the detection of DNA MMR defects. (S)
Note: MSI by NGS assay must be validated against MMR-IHC or MSI by PCR and must show equivalency.
324662
Title
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
Authoring Organizations
Association for Molecular Pathology
College of American Pathologists